https://pharminent.com/blackstone-to-fund-pfizers-monthly-glp-1-with-up-to-1-5b/ 2026-11-12T12:45:51Z Pharminent en Blackstone to fund Pfizer's monthly GLP-1 with up to $1.5B 2026-11-12T12:45:51Z Blog https://pharminent.com/neuromarket-pulse/neuromarket-pulse-weekly-neuroscience-competitive-intelligence-november-11-2026/ 2026-11-12T02:38:43Z Pharminent en NeuroMarket Pulse • Weekly Neuroscience Competitive Intelligence • November 11, 2026 2026-11-12T02:38:43Z Blog https://pharminent.com/manufacturing-intelligence/manufacturing-intelligence-weekly-digest-november-11-2026/ 2026-11-12T02:37:57Z Pharminent en Manufacturing Intelligence • Weekly Digest • November 11, 2026 2026-11-12T02:37:57Z Blog https://pharminent.com/oncology/oncology-intelligence-digest-november-10-2026/ 2026-11-11T17:24:23Z Pharminent en Oncology Intelligence Digest • November 10, 2026 2026-11-11T17:24:23Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-november-11-2026/ 2026-11-11T17:24:01Z Pharminent en Strategic News Watch • November 11, 2026 2026-11-11T17:24:01Z Blog https://pharminent.com/fda-approves-bayers-sunharbo-for-secondary-stroke-prevention/ 2026-11-11T12:59:13Z Pharminent en Beam’s base editing sickle cell therapy meets pivotal trial goal 2026-11-11T12:45:45Z Blog https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-november-9-2026/ 2026-11-10T18:33:43Z Pharminent en Rare Disease & Gene Therapy Digest • November 9, 2026 2026-11-10T18:33:43Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-november-10-2026/ 2026-11-10T18:33:03Z Pharminent en Strategic News Watch • November 10, 2026 2026-11-10T18:33:03Z Blog https://pharminent.com/fda-approves-bayers-sunharbo-first-factor-xia-inhibitor/ 2026-11-10T12:45:50Z Pharminent en FDA approves Bayer's Sunharbo, first factor XIa inhibitor 2026-11-10T12:45:50Z Blog